June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...
"Marshall’s rich experience strengthens our board as we move into our next phase of growth," CEO Maggie Nixon said.
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...
AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...
AbbVie announced this morning it would buy clinical-stage biotech company Capstan Therapeutics for up to $2.1 billion in cash, picking up the company's in vivo CAR-T therapy candidate. San Diego-based ...
A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the body is being acquired by pharmaceutical giant AbbVie for $2.1 billion in ...
Capstan Medical, a developer of robotic-enabled, minimally invasive solutions to address heart valve disease, today announced ...
SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...
(Reuters) -U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion, expanding its pipeline with experimental treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback